Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.

J Thromb Thrombolysis. 2019 Jan;47(1):155-156. doi: 10.1007/s11239-018-1773-4. No abstract available.

PMID:
30478722
2.

Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Castelli R, Schiavon R, Rossi V, Deliliers GL.

Med Oncol. 2018 Apr 19;35(5):76. doi: 10.1007/s12032-018-1135-2. Review.

PMID:
29675620
3.

The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.

Castelli R, Schiavon R, Deliliers GL.

Med Oncol. 2018 Feb 8;35(3):33. doi: 10.1007/s12032-018-1094-7.

PMID:
29417235
4.

First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Castelli R, Bergamaschini L, Deliliers GL.

Med Oncol. 2017 Dec 29;35(2):15. doi: 10.1007/s12032-017-1076-1.

PMID:
29288421
5.

High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.

J Thromb Thrombolysis. 2018 Jan;45(1):106-113. doi: 10.1007/s11239-017-1566-1.

PMID:
29022213
6.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T.

J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2.

PMID:
28463633
7.

Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients.

Castelli R, Gidaro A, Deliliers GL.

Mediterr J Hematol Infect Dis. 2016 Jul 1;8(1):e2016030. doi: 10.4084/MJHID.2016.030. eCollection 2016.

8.

Laboratory and clinical risk assessment to treat myelodysplatic syndromes.

Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R.

Clin Chem Lab Med. 2016 Sep 1;54(9):1411-26. doi: 10.1515/cclm-2015-0789. Review.

9.

Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.

Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P, Pantaleo G.

Ann Hematol. 2014 Sep;93(9):1523-9. doi: 10.1007/s00277-014-2070-8. Epub 2014 Apr 8.

PMID:
24711171
10.

Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).

Scavullo C, Servida F, Lecis D, Onida F, Drago C, Ferrante L, Seneci P, Barcellini W, Lionetti M, Todoerti K, Neri A, Delia D, Deliliers GL.

Leuk Res. 2013 Jul;37(7):809-15. doi: 10.1016/j.leukres.2013.03.016. Epub 2013 Apr 22.

PMID:
23618690
11.

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.

Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F.

Leukemia. 2013 Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18.

PMID:
23417029
12.

Metabolic syndrome in patients with hematological diseases.

Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL.

Expert Rev Hematol. 2012 Aug;5(4):439-58. Review.

PMID:
22992237
13.

Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease.

Cova L, Bossolasco P, Armentero MT, Diana V, Zennaro E, Mellone M, Calzarossa C, Cerri S, Deliliers GL, Polli E, Blandini F, Silani V.

Apoptosis. 2012 Mar;17(3):289-304. doi: 10.1007/s10495-011-0679-9.

PMID:
22160861
14.

Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease.

Clerici M, Cassinotti A, Onida F, Trabattoni D, Annaloro C, Della Volpe A, Rainone V, Lissoni F, Duca P, Sampietro G, Fociani P, Vago G, Foschi D, Ardizzone S, Deliliers GL, Porro GB.

Dig Liver Dis. 2011 Dec;43(12):946-52. doi: 10.1016/j.dld.2011.07.021. Epub 2011 Sep 9.

PMID:
21907652
15.

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA.

Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12.

16.

Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial.

Colombo A, Castellani M, Piccaluga E, Pusineri E, Palatresi S, Longari V, Canzi C, Sacchi E, Rossi E, Rech R, Gerundini P, Viecca M, Deliliers GL, Rebulla P, Soligo D, Giordano R.

J Cardiovasc Med (Hagerstown). 2011 Apr;12(4):239-48. doi: 10.2459/JCM.0b013e328343d708.

PMID:
21372740
17.

Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects.

Fracchiolla NS, Todoerti K, Bertazzi PA, Servida F, Corradini P, Carniti C, Colombi A, Cecilia Pesatori A, Neri A, Deliliers GL.

Toxicology. 2011 Apr 28;283(1):18-23. doi: 10.1016/j.tox.2011.01.025. Epub 2011 Feb 4.

PMID:
21296121
18.

Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.

Boiocchi L, Vener C, Savi F, Bonoldi E, Moro A, Fracchiolla NS, Iurlo A, Deliliers GL, Coggi G, Bosari S, Gianelli U.

J Clin Pathol. 2011 Mar;64(3):226-31. doi: 10.1136/jcp.2010.083386. Epub 2011 Jan 8.

PMID:
21217153
19.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846.

PMID:
21146205
20.

Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.

Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F, Cutrona G, Andronache A, Matis S, Ferrari F, Gentile M, Spriano M, Callea V, Festini G, Molica S, Deliliers GL, Bicciato S, Ferrarini M, Neri A.

Clin Cancer Res. 2010 Dec 1;16(23):5641-53. doi: 10.1158/1078-0432.CCR-10-0151. Epub 2010 Oct 14.

21.

Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.

Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, Matis S, Grazia Recchia A, Gigliotti V, Gentile M, Deliliers GL, Bertazzi PA, Ferrarini M, Neri A, Baccarelli A.

Epigenetics. 2011 Feb;6(2):188-94. Epub 2011 Feb 1.

22.

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarría E, Schmitz N, Sureda A.

J Clin Oncol. 2010 Oct 10;28(29):4492-9. doi: 10.1200/JCO.2010.29.3241. Epub 2010 Aug 9.

PMID:
20697072
23.

Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis.

Vener C, Novembrino C, Catena FB, Fracchiolla NS, Gianelli U, Savi F, Radaelli F, Fermo E, Cortelezzi A, Lonati S, Menegatti M, Deliliers GL.

Exp Hematol. 2010 Nov;38(11):1058-65. doi: 10.1016/j.exphem.2010.07.005. Epub 2010 Jul 22.

PMID:
20655352
24.

Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers.

Ferri C, Giuggioli D, Manfredi A, Quirici N, Scavullo C, Colaci M, Gianelli U, Deliliers GL, Del Papa N.

Clin Exp Dermatol. 2010 Dec;35(8):885-7. doi: 10.1111/j.1365-2230.2010.03847.x.

PMID:
20456380
25.

Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.

Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M.

Bone Marrow Transplant. 2011 Jan;46(1):125-31. doi: 10.1038/bmt.2010.70. Epub 2010 Apr 12.

PMID:
20383209
26.

Anti-L-NGFR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue.

Quirici N, Scavullo C, de Girolamo L, Lopa S, Arrigoni E, Deliliers GL, Brini AT.

Stem Cells Dev. 2010 Jun;19(6):915-25. doi: 10.1089/scd.2009.0408.

27.

Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.

Blandini F, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P, Calzarossa C, Mellone M, Giuseppe B, Deliliers GL, Polli E, Nappi G, Silani V.

Cell Transplant. 2010;19(2):203-17. doi: 10.3727/096368909X479839. Epub 2009 Nov 10.

PMID:
19906332
28.

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A.

Blood. 2009 Dec 10;114(25):e20-6. doi: 10.1182/blood-2009-08-237495.

29.

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G, Sarina B, Musto P, Barcellini W, Neri A, Deliliers GL.

Leukemia. 2009 Nov;23(11):2027-33. doi: 10.1038/leu.2009.148. Epub 2009 Jul 30.

30.

Differential repetitive DNA methylation in multiple myeloma molecular subgroups.

Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, Motta V, Bertazzi PA, Baccarelli A, Neri A.

Carcinogenesis. 2009 Aug;30(8):1330-5. doi: 10.1093/carcin/bgp149. Epub 2009 Jun 16.

PMID:
19531770
31.

A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.

Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Deliliers GL, Neri A.

Genes Chromosomes Cancer. 2009 Jul;48(7):603-14. doi: 10.1002/gcc.20668.

PMID:
19396863
32.

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL, Neri A.

Genes Chromosomes Cancer. 2009 Jun;48(6):521-31. doi: 10.1002/gcc.20660.

PMID:
19306352
33.

Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients.

Annaloro C, Olivares C, Usardi P, Onida F, Della Volpe A, Tagliaferri E, Deliliers GL.

J Antimicrob Chemother. 2009 Mar;63(3):625-6. doi: 10.1093/jac/dkn549. Epub 2009 Jan 21. No abstract available.

PMID:
19158110
34.

In vitro anti-leukaemia activity of sphingosine kinase inhibitor.

Ricci C, Onida F, Servida F, Radaelli F, Saporiti G, Todoerti K, Deliliers GL, Ghidoni R.

Br J Haematol. 2009 Feb;144(3):350-7. doi: 10.1111/j.1365-2141.2008.07474.x. Epub 2008 Nov 19.

PMID:
19036099
35.

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.

Verdelli D, Nobili L, Todoerti K, Intini D, Cosenza M, Civallero M, Bertacchini J, Deliliers GL, Sacchi S, Lombardi L, Neri A.

Hematol Oncol. 2009 Mar;27(1):23-30. doi: 10.1002/hon.875.

PMID:
18759374
36.

The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.

Gianelli U, Iurlo A, Vener C, Moro A, Fermo E, Bianchi P, Graziani D, Radaelli F, Coggi G, Bosari S, Deliliers GL, Zanella A.

Am J Clin Pathol. 2008 Sep;130(3):336-42. doi: 10.1309/6BQ5K8LHVYAKUAF4.

PMID:
18701405
37.

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, Deliliers GL, Neri A.

BMC Med Genomics. 2008 Aug 13;1:37. doi: 10.1186/1755-8794-1-37.

38.

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S.

Leuk Lymphoma. 2008 Jul;49(7):1374-83. doi: 10.1080/10428190802078289.

PMID:
18452078
39.

Conjunctival hemorrhagic events associated with imatinib mesylate.

Radaelli F, Vener C, Ripamonti F, Iurlo A, Colombi M, Artoni A, Reda G, Deliliers GL.

Int J Hematol. 2007 Dec;86(5):390-3. doi: 10.1532/IJH97.E0741.

PMID:
18192104
40.

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.

Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, Caberlon S, Gerli G, Boiocchi L, Deliliers GL.

Blood. 2008 Feb 15;111(4):1862-5. Epub 2007 Nov 20.

41.

VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.

Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, Iurlo A, Radaelli F, Fermo E, Bucciarelli P, Bori S, Coggi G, Deliliers GL.

Am J Clin Pathol. 2007 Dec;128(6):966-73.

PMID:
18024322
42.

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.

Cassinotti A, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL.

Gut. 2008 Feb;57(2):211-7. Epub 2007 Sep 25.

PMID:
17895357
43.

Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status.

Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, Cortiana M, Parati G, Onida F, Sozzi F, Vener C, Bianchi P, Deliliers GL.

Leukemia. 2008 Mar;22(3):646-9. Epub 2007 Sep 13. No abstract available.

PMID:
17851555
44.

Invasive fungal sinusitis: an effective combined treatment in five haematological patients.

Vener C, Carrabba M, Fracchiolla NS, Costa A, Fabio G, Hu C, Sina C, Guastella C, Pignataro L, Deliliers GL.

Leuk Lymphoma. 2007 Aug;48(8):1577-86.

PMID:
17701590
45.

Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.

Gianelli U, Fracchiolla NS, Cortelezzi A, Pellegrini C, Savi F, Moro A, Grimoldi MG, Deliliers GL, Coggi G, Bosari S.

Ann Hematol. 2007 Mar;86(3):185-9. Epub 2006 Nov 24.

PMID:
17124585
46.

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, Somalvico F, Radaelli F, Franco V, Deliliers GL.

Leuk Lymphoma. 2006 Sep;47(9):1774-81.

PMID:
17064987
47.

Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential.

Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Buiatiotis S, Soligo D, Bosari S, Silani V, Deliliers GL, Rebulla P, Lazzari L.

Cell Res. 2006 Apr;16(4):329-36.

48.

A long-term follow-up analysis in adult acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Annaloro C, Zilioli VR, Fracchiolla NS, Vener C, Soligo D, Della Volpe A, Deliliers GL.

Tumori. 2005 Sep-Oct;91(5):388-93.

PMID:
16459634
49.

ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia.

Vener C, Gianelli U, Cortelezzi A, Fracchiolla NS, Somalvico F, Savi F, Pasquini MC, Bosari S, Deliliers GL.

Leuk Lymphoma. 2006 Feb;47(2):245-51.

PMID:
16321853
50.

Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.

Cortelezzi A, Viganò M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, Colombo M, Lampertico P.

J Clin Virol. 2006 Apr;35(4):467-9. Epub 2005 Nov 28.

PMID:
16316778

Supplemental Content

Loading ...
Support Center